![]() Patients who have had prior autologous or allogeneic transplants or CAR-T cell therapy are eligible. Additionally, patients must have adequate blood counts and organ function. We are enrolling patients with relapsed/refractory MM by IMWG criteria with measurable disease defined by the detection of a quantifiable monoclonal protein in the urine or serum or an abnormal serum free light chain ratio. individual IC50s, AUCs and/or synergy scores) to accurately predict response to combination therapy that was given prospectively to all enrolled patients. This study's objective is to directly demonstrate the utility of a high throughput drug sensitivity assay in determining biomarkers (e.g. In this ongoing trial, Panobinostat with Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation with In Vitro Chemosensitivity Testing (NCT03256045), we will correlate individual patient in vitro sensitivity assay results with individual clinical response to the same triple drug regimen. ![]() We developed an in vitro high throughput drug sensitivity assay with formal synergy testing to predict response. ![]() A test that could predict patient responses to specific agents might enable clinicians to optimize therapy for patients, improving outcomes. With the heterogeneity of MM, individual patients exhibit wide variability in responses to drug combinations. Panobinostat and carfilzomib has also been shown to be a highly active regimen in relapsed/refractory MM with an overall response rate of up to 75% (Berdeja et al, Haematologica, 2015). Carfilzomib is a proteasome inhibitor that was FDA approved in relapsed/refractory MM with the advantage of minimal neuropathy. Panobinostat, bortezomib, dexamethasone was shown to be an effective regimen (San Miguel et al Lancet Hematol 2016 Richardson et al Blood 2016), leading to the FDA approval of panobinostat for patients with relapsed/refractory MM. Panobinostat is a pan-inhibitor of histone deacetylases types I,II, and IV. J Physiol 556(Pt 1):267–282ĭ’Avella A, Portone A, Fernandez L, Lacquaniti F (2006) Control of fast-reaching movements by muscle synergy combinations.The treatment of multiple myeloma (MM) is optimized by use of combination regimens consisting of agents with different mechanisms of action. Ivanenko YP, Poppele RE, Lacquaniti F (2004) Five basic muscle activation patterns account for muscle activity during human locomotion. Krishnamoorthy V, Goodman S, Zatsiorsky V, Latash ML (2003) Muscle synergies during shifts of the center of pressure by standing persons: identification of muscle modes. Torres-Oviedo G, Macpherson JM, Ting LH (2006) Muscle synergy organization is robust across a variety of postural perturbations. Hart CB, Giszter SF (2004) Modular premotor drives and unit bursts as primitives for frog motor behaviors. ![]() Tresch MC, Saltiel P, Bizzi E (1999) The construction of movement by the spinal cord. Cereb Cortex 17(4):803–815ĭ’Avella A, Saltiel P, Bizzi E (2003) Combinations of muscle synergies in the construction of a natural motor behavior. ![]() Klein Breteler MD, Simura KJ, Flanders M (2007) Timing of muscle activation in a hand movement sequence. Tresch MC, Cheung VC, d’Avella A (2006) Matrix factorization algorithms for the identification of muscle synergies: evaluation on simulated and experimental data sets. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |